Literature DB >> 28696023

MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment.

Tommi Tervonen1, Heather Gelhorn2, Sumitra Sri Bhashyam1, Jiat-Ling Poon2, Katharine S Gries3, Anne Rentz2, Kevin Marsh1.   

Abstract

PURPOSE: Multiple criteria decision analysis swing weighting (SW) and discrete choice experiments (DCE) are appropriate methods for capturing patient preferences on treatment benefit-risk trade-offs. This paper presents a qualitative comparison of the 2 methods.
METHODS: We review and critically assess similarities and differences of SW and DCE based on 6 aspects: comprehension by study participants, cognitive biases, sample representativeness, ability to capture heterogeneity in preferences, reliability and validity, and robustness of the results.
RESULTS: The SW choice task can be more difficult, but the workshop context in which SW is conducted may provide more support to patients who are unfamiliar with the end points being evaluated or who have cognitive impairments. Both methods are similarly prone to a number of biases associated with preference elicitation, and DCE is prone to simplifying heuristics, which limits its application with large number of attributes. The low cost per patient of the DCE means that it can be better at achieving a representative sample, though SW does not require such large sample sizes due to exact nature of the collected preference data. This also means that internal validity is automatically enforced with SW, while the internal validity of DCE results needs to be assessed manually.
CONCLUSIONS: Choice between the 2 methods depends on characteristics of the benefit-risk assessment, especially on how difficult the trade-offs are for the patients to make and how many patients are available. Although there exist some empirical studies on many of the evaluation aspects, critical evidence gaps remain.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  benefit-risk assessment; discrete choice experiment; multicriteria decision analysis; pharmacoepidemiology; swing weighting

Mesh:

Year:  2017        PMID: 28696023     DOI: 10.1002/pds.4255

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  18 in total

1.  Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences.

Authors:  Christopher Weyant; Margaret L Brandeau; Sanjay Basu
Journal:  Med Decis Making       Date:  2019-11-09       Impact factor: 2.583

2.  Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.

Authors:  Sung Eun Choi; Seth A Berkowitz; John S Yudkin; Huseyin Naci; Sanjay Basu
Journal:  Med Decis Making       Date:  2019-02-15       Impact factor: 2.583

3.  Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?

Authors:  David John Mott
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

4.  Using Eye-Tracking Technology with Older People in Memory Clinics to Investigate the Impact of Mild Cognitive Impairment on Choices for EQ-5D-5L Health States Preferences.

Authors:  Kaiying Wang; Chris Barr; Richard Norman; Stacey George; Craig Whitehead; Julie Ratcliffe
Journal:  Appl Health Econ Health Policy       Date:  2021-01       Impact factor: 2.561

5.  A Bayesian approach for individual-level drug benefit-risk assessment.

Authors:  Kan Li; Sheng Luo; Sammy Yuan; Shahrul Mt-Isa
Journal:  Stat Med       Date:  2019-04-15       Impact factor: 2.373

6.  A Systematic Review of Discrete Choice Experiments in Oncology Treatments.

Authors:  Hannah Collacott; Vikas Soekhai; Caitlin Thomas; Anne Brooks; Ella Brookes; Rachel Lo; Sarah Mulnick; Sebastian Heidenreich
Journal:  Patient       Date:  2021-05-05       Impact factor: 3.883

7.  A novel measure of drug benefit-risk assessment based on Scale Loss Score.

Authors:  Gaelle Saint-Hilary; Veronique Robert; Mauro Gasparini; Thomas Jaki; Pavel Mozgunov
Journal:  Stat Methods Med Res       Date:  2018-07-20       Impact factor: 3.021

8.  Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study.

Authors:  Rosanne Janssens; Tamika Lang; Ana Vallejo; Jayne Galinsky; Ananda Plate; Kate Morgan; Elena Cabezudo; Raija Silvennoinen; Daniel Coriu; Sorina Badelita; Ruxandra Irimia; Minna Anttonen; Riikka-Leena Manninen; Elise Schoefs; Martina Vandebroek; Anneleen Vanhellemont; Michel Delforge; Hilde Stevens; Steven Simoens; Isabelle Huys
Journal:  Front Med (Lausanne)       Date:  2021-07-06

Review 9.  Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA).

Authors:  Maureen Rutten-van Mölken; Fenna Leijten; Maaike Hoedemakers; Apostolos Tsiachristas; Nick Verbeek; Milad Karimi; Roland Bal; Antoinette de Bont; Kamrul Islam; Jan Erik Askildsen; Thomas Czypionka; Markus Kraus; Mirjana Huic; János György Pitter; Verena Vogt; Jonathan Stokes; Erik Baltaxe
Journal:  BMC Health Serv Res       Date:  2018-07-24       Impact factor: 2.655

10.  Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review.

Authors:  Rosanne Janssens; Isabelle Huys; Eline van Overbeeke; Chiara Whichello; Sarah Harding; Jürgen Kübler; Juhaeri Juhaeri; Antonio Ciaglia; Steven Simoens; Hilde Stevens; Meredith Smith; Bennett Levitan; Irina Cleemput; Esther de Bekker-Grob; Jorien Veldwijk
Journal:  BMC Med Inform Decis Mak       Date:  2019-10-04       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.